Cargando…

Spontaneous apoptosis of blood dendritic cells in patients with breast cancer

INTRODUCTION: Dendritic cells (DCs) are key antigen-presenting cells that play an essential role in initiating and directing cellular and humoral immunity, including anti-tumor responses. Due to their critical role in cancer, induction of DC apoptosis may be one of the central mechanisms used by tum...

Descripción completa

Detalles Bibliográficos
Autores principales: Pinzon-Charry, Alberto, Maxwell, Tammy, McGuckin, Michael A, Schmidt, Chris, Furnival, Colin, López, J Alejandro
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1413992/
https://www.ncbi.nlm.nih.gov/pubmed/16417648
http://dx.doi.org/10.1186/bcr1361
_version_ 1782127099112325120
author Pinzon-Charry, Alberto
Maxwell, Tammy
McGuckin, Michael A
Schmidt, Chris
Furnival, Colin
López, J Alejandro
author_facet Pinzon-Charry, Alberto
Maxwell, Tammy
McGuckin, Michael A
Schmidt, Chris
Furnival, Colin
López, J Alejandro
author_sort Pinzon-Charry, Alberto
collection PubMed
description INTRODUCTION: Dendritic cells (DCs) are key antigen-presenting cells that play an essential role in initiating and directing cellular and humoral immunity, including anti-tumor responses. Due to their critical role in cancer, induction of DC apoptosis may be one of the central mechanisms used by tumors to evade immune recognition. METHODS: Spontaneous apoptosis of blood DCs (lineage negative HLA-DR positive cells) was assessed in peripheral blood mononuclear cells (PBMCs) using Annexin-V and TUNEL assays immediately after blood collection. The role of tumor products was assessed by culturing cells with supernatants derived from breast cancer cell lines (TDSN) or PBMCs (PBMC-SN, as a control). The capacity of DC stimulation to prevent apoptosis was assessed by incubating DC with inflammatory cytokines, poly I:C, IL-12 or CD40 ligand (CD40L) prior to culture with TDSN. Apoptosis was determined by flow cytometry and microscopy, and Bcl-2 expression determined by intracellular staining. RESULTS: In this study we document the presence of a significantly higher proportion of apoptotic (Annexin-V(+ )and TUNEL(+)) blood DCs in patients with early stage breast cancer (stage I to II; n = 13) compared to healthy volunteers (n = 15). We examined the role of tumor products in this phenomenon and show that supernatants derived from breast cancer lines induce apoptosis of blood DCs in PBMC cultures. Aiming to identify factors that protect blood DC from apoptosis, we compared a range of clinically available maturation stimuli, including inflammatory cytokines (tumor necrosis factor-α, IL-1β, IL-6 and prostaglandin (PG)E(2 )as a cytokine cocktail), synthetic double-stranded RNA (poly I:C) and soluble CD40 ligand. Although inflammatory cytokines and poly I:C induced robust phenotypic maturation, they failed to protect blood DCs from apoptosis. In contrast, CD40 stimulation induced strong antigen uptake, secretion of IL-12 and protected blood DCs from apoptosis through sustained expression of Bcl-2. Exogenous IL-12 provided similar Bcl-2 mediated protection, suggesting that CD40L effect is mediated, at least in part, through IL-12 secretion. CONCLUSION: Cumulatively, our results demonstrate spontaneous apoptosis of blood DCs in patients with breast cancer and confirm that ex vivo conditioning of blood DCs can protect them from tumor-induced apoptosis.
format Text
id pubmed-1413992
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-14139922006-03-27 Spontaneous apoptosis of blood dendritic cells in patients with breast cancer Pinzon-Charry, Alberto Maxwell, Tammy McGuckin, Michael A Schmidt, Chris Furnival, Colin López, J Alejandro Breast Cancer Res Research Article INTRODUCTION: Dendritic cells (DCs) are key antigen-presenting cells that play an essential role in initiating and directing cellular and humoral immunity, including anti-tumor responses. Due to their critical role in cancer, induction of DC apoptosis may be one of the central mechanisms used by tumors to evade immune recognition. METHODS: Spontaneous apoptosis of blood DCs (lineage negative HLA-DR positive cells) was assessed in peripheral blood mononuclear cells (PBMCs) using Annexin-V and TUNEL assays immediately after blood collection. The role of tumor products was assessed by culturing cells with supernatants derived from breast cancer cell lines (TDSN) or PBMCs (PBMC-SN, as a control). The capacity of DC stimulation to prevent apoptosis was assessed by incubating DC with inflammatory cytokines, poly I:C, IL-12 or CD40 ligand (CD40L) prior to culture with TDSN. Apoptosis was determined by flow cytometry and microscopy, and Bcl-2 expression determined by intracellular staining. RESULTS: In this study we document the presence of a significantly higher proportion of apoptotic (Annexin-V(+ )and TUNEL(+)) blood DCs in patients with early stage breast cancer (stage I to II; n = 13) compared to healthy volunteers (n = 15). We examined the role of tumor products in this phenomenon and show that supernatants derived from breast cancer lines induce apoptosis of blood DCs in PBMC cultures. Aiming to identify factors that protect blood DC from apoptosis, we compared a range of clinically available maturation stimuli, including inflammatory cytokines (tumor necrosis factor-α, IL-1β, IL-6 and prostaglandin (PG)E(2 )as a cytokine cocktail), synthetic double-stranded RNA (poly I:C) and soluble CD40 ligand. Although inflammatory cytokines and poly I:C induced robust phenotypic maturation, they failed to protect blood DCs from apoptosis. In contrast, CD40 stimulation induced strong antigen uptake, secretion of IL-12 and protected blood DCs from apoptosis through sustained expression of Bcl-2. Exogenous IL-12 provided similar Bcl-2 mediated protection, suggesting that CD40L effect is mediated, at least in part, through IL-12 secretion. CONCLUSION: Cumulatively, our results demonstrate spontaneous apoptosis of blood DCs in patients with breast cancer and confirm that ex vivo conditioning of blood DCs can protect them from tumor-induced apoptosis. BioMed Central 2006 2005-12-16 /pmc/articles/PMC1413992/ /pubmed/16417648 http://dx.doi.org/10.1186/bcr1361 Text en Copyright © 2005 Pinzon-Charry et al.; licensee BioMed Central Ltd.
spellingShingle Research Article
Pinzon-Charry, Alberto
Maxwell, Tammy
McGuckin, Michael A
Schmidt, Chris
Furnival, Colin
López, J Alejandro
Spontaneous apoptosis of blood dendritic cells in patients with breast cancer
title Spontaneous apoptosis of blood dendritic cells in patients with breast cancer
title_full Spontaneous apoptosis of blood dendritic cells in patients with breast cancer
title_fullStr Spontaneous apoptosis of blood dendritic cells in patients with breast cancer
title_full_unstemmed Spontaneous apoptosis of blood dendritic cells in patients with breast cancer
title_short Spontaneous apoptosis of blood dendritic cells in patients with breast cancer
title_sort spontaneous apoptosis of blood dendritic cells in patients with breast cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1413992/
https://www.ncbi.nlm.nih.gov/pubmed/16417648
http://dx.doi.org/10.1186/bcr1361
work_keys_str_mv AT pinzoncharryalberto spontaneousapoptosisofblooddendriticcellsinpatientswithbreastcancer
AT maxwelltammy spontaneousapoptosisofblooddendriticcellsinpatientswithbreastcancer
AT mcguckinmichaela spontaneousapoptosisofblooddendriticcellsinpatientswithbreastcancer
AT schmidtchris spontaneousapoptosisofblooddendriticcellsinpatientswithbreastcancer
AT furnivalcolin spontaneousapoptosisofblooddendriticcellsinpatientswithbreastcancer
AT lopezjalejandro spontaneousapoptosisofblooddendriticcellsinpatientswithbreastcancer